Two Investing Legends Join Forces for One Night ONLY…

and reveal the massive market events that will shape 2020 — and what they recommend you do NOW with your money.

Tue, December 10 at 7:00PM ET
 
 
 
 

10 Pharmaceuticals Stocks to Buy Now

10 Pharmaceuticals Stocks to Buy Now

10 Pharmaceuticals stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).

This is a strong week for GW Pharmaceuticals PLC Sponsored ADR (GWPH). The company’s rating climbs to B from the previous week’s C. The company also gets A’s in earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of GWPH stock.

This week, Merck & Co., Inc.’s (MRK) ratings are up from a B last week to a A. Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company also gets A’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of MRK stock.

Aerie Pharmaceuticals, Inc. (AERI) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of AERI stock.

Dermira Inc (DERM) earns a B this week, jumping up from last week’s grade of C. For more information, get Portfolio Grader’s complete analysis of DERM stock.

This week, Depomed, Inc. (DEPO) pushes up from a C to a B rating. Depomed, Inc. develops new and proprietary oral drug delivery technologies. The company also gets A’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of DEPO stock.

Supernus Pharmaceuticals, Inc. (SUPN) is seeing ratings go up from a B last week to a A this week. Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets proprietary drugs for the treatment of central nervous system diseases and disorders. The company also gets A’s in sales growth, earnings growth, earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of SUPN stock.

Corcept Therapeutics Incorporated. (CORT) gets a higher grade this week, advancing from a C last week to a B. Corcept Therapeutics Incorporated. engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of CORT stock.

NovaBay Pharmaceuticals, Inc. (NBY) boosts its rating from a C to a B this week. NovaBay Pharmaceuticals, Inc. develops product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. The company also gets A’s in sales growth and earnings revisions. For more information, get Portfolio Grader’s complete analysis of NBY stock.

The rating of SteadyMed Ltd. (STDY) moves up this week, rising from a C to a B. For more information, get Portfolio Grader’s complete analysis of STDY stock.

Intellipharmaceutics International Inc.’s (IPCI) ratings are looking better this week, moving up to a B from last week’s C. Intellipharmaceutics International Inc. develops drug delivery technologies. For more information, get Portfolio Grader’s complete analysis of IPCI stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/10/10-pharmaceuticals-stocks-to-buy-now-2/.

©2019 InvestorPlace Media, LLC